JP5725711B2 - 癌治療法を有する患者の同定、評価、および治療のための方法 - Google Patents

癌治療法を有する患者の同定、評価、および治療のための方法 Download PDF

Info

Publication number
JP5725711B2
JP5725711B2 JP2009523844A JP2009523844A JP5725711B2 JP 5725711 B2 JP5725711 B2 JP 5725711B2 JP 2009523844 A JP2009523844 A JP 2009523844A JP 2009523844 A JP2009523844 A JP 2009523844A JP 5725711 B2 JP5725711 B2 JP 5725711B2
Authority
JP
Japan
Prior art keywords
predictive
marker
markers
expression
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009523844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500565A (ja
JP2010500565A5 (enExample
Inventor
バーバラ エム． ブライアント，
バーバラ エム． ブライアント，
アンドリュー アイ． ダモコシュ，
アンドリュー アイ． ダモコシュ，
ジョージ マリガン，
ジョージ マリガン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2010500565A publication Critical patent/JP2010500565A/ja
Publication of JP2010500565A5 publication Critical patent/JP2010500565A5/ja
Application granted granted Critical
Publication of JP5725711B2 publication Critical patent/JP5725711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009523844A 2006-08-10 2007-08-09 癌治療法を有する患者の同定、評価、および治療のための方法 Active JP5725711B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83676406P 2006-08-10 2006-08-10
US60/836,764 2006-08-10
PCT/US2007/017716 WO2008021183A2 (en) 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy

Publications (3)

Publication Number Publication Date
JP2010500565A JP2010500565A (ja) 2010-01-07
JP2010500565A5 JP2010500565A5 (enExample) 2010-09-24
JP5725711B2 true JP5725711B2 (ja) 2015-05-27

Family

ID=39082605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523844A Active JP5725711B2 (ja) 2006-08-10 2007-08-09 癌治療法を有する患者の同定、評価、および治療のための方法

Country Status (7)

Country Link
US (1) US9500656B2 (enExample)
EP (1) EP2046973A4 (enExample)
JP (1) JP5725711B2 (enExample)
AU (1) AU2007284724B2 (enExample)
CA (1) CA2660275A1 (enExample)
MX (1) MX2009001489A (enExample)
WO (1) WO2008021183A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279417B1 (en) * 2008-05-28 2016-07-20 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010019921A2 (en) * 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
WO2010107960A1 (en) * 2009-03-17 2010-09-23 Brody Jonathan R Methods for assessing the efficacy of gemcitabine or ara-c treatment of cancer using human antigen r levels
CA2758229A1 (en) * 2009-04-17 2010-10-21 University Health Network Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
CA2758826A1 (en) * 2009-04-18 2010-10-21 Merck Sharp & Dohme Corp. Methods and gene expression signature for assessing ras pathway activity
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2011044513A1 (en) * 2009-10-08 2011-04-14 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
US9551034B2 (en) 2010-01-11 2017-01-24 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2012024612A1 (en) * 2010-08-20 2012-02-23 Pangea Biosciences, Inc. Cancer diagnostic and cancer therapeutic
WO2013023132A1 (en) 2011-08-10 2013-02-14 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
HRP20160851T1 (hr) 2011-08-11 2016-09-23 Janssen Pharmaceutica N.V. Prediktori za liječenje karcinoma
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
PT3387898T (pt) * 2013-03-15 2020-06-17 Mayo Found Medical Education & Res Identificação e monitorização de imunoglobulinas monoclonais pela massa molecular
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US10181008B2 (en) 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US20150287143A1 (en) * 2014-04-03 2015-10-08 John Hancock Life Insurance Company (U.S.A.) System and method for managing underwriting using a risk order approach
JP6759104B2 (ja) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
JP6675990B2 (ja) * 2014-05-20 2020-04-08 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 多発性骨髄腫の治療方法
US10690676B2 (en) 2014-07-29 2020-06-23 Mayo Roundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by LC-MS/MS
JP6968058B2 (ja) 2015-09-24 2021-11-17 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 質量分析法による免疫グロブリン遊離軽鎖の同定
JP6681475B2 (ja) * 2015-10-26 2020-04-15 サイフェローム がん患者のゲノム塩基配列変異情報と生存情報を利用したカスタマイズ型の薬物選択方法及びシステム
US10955420B2 (en) 2016-09-07 2021-03-23 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
AU2018258683A1 (en) 2017-04-28 2019-12-19 University Of Southern California System and method for predicting survival time
WO2019055632A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN CHAINS J
EP3681528B1 (en) 2017-09-13 2025-07-23 Mayo Foundation for Medical Education and Research Identification and monitoring of apoptosis inhibitor of macrophage
CN110108878A (zh) * 2019-05-30 2019-08-09 四川大学华西医院 Eif2s1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05296999A (ja) * 1992-04-24 1993-11-12 Amano Pharmaceut Co Ltd グルココルチコイドの効果判定マーカーとしてのヒトリポコルチンｉ及びその定量法
JP2004248502A (ja) * 2000-10-05 2004-09-09 Takara Holdings Inc 癌悪性度の評価方法
EP1498825A1 (en) * 2002-04-04 2005-01-19 Ishihara Sangyo Kaisha, Ltd. Apparatus and method for analyzing data
MXPA05005923A (es) * 2002-12-06 2005-09-21 Millennium Pharm Inc Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US7741035B2 (en) * 2004-05-21 2010-06-22 Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
EP2687608B1 (en) * 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy

Also Published As

Publication number Publication date
WO2008021183A2 (en) 2008-02-21
WO2008021183A9 (en) 2008-07-24
EP2046973A4 (en) 2010-04-07
JP2010500565A (ja) 2010-01-07
EP2046973A2 (en) 2009-04-15
US9500656B2 (en) 2016-11-22
MX2009001489A (es) 2009-02-18
AU2007284724A1 (en) 2008-02-21
AU2007284724B2 (en) 2014-03-13
CA2660275A1 (en) 2008-02-21
US20080064055A1 (en) 2008-03-13
WO2008021183A3 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
JP2010500565A (ja) 癌治療法を有する患者の同定、評価、および治療のための方法
JP5904569B2 (ja) 癌治療を受けている患者の同定、判定および処置のための方法
JP5896593B2 (ja) プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
JP6486826B2 (ja) 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
US20160312309A1 (en) Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
JP6238900B2 (ja) Ｎａｅ阻害物質に対する応答のバイオマーカー
JP6286358B2 (ja) プロテアソーム阻害剤に応答するバイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110725

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130408

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130430

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150331

R150 Certificate of patent or registration of utility model

Ref document number: 5725711

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250